Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Dow
Merck
Boehringer Ingelheim
Medtronic

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR TYGACIL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Tygacil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00481962 ↗ Health Economic Assessment of Tygacil┬« in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs) Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-02-01 The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).
NCT00488345 ↗ Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 2 2007-12-01 To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), or community-acquired pneumonia (CAP).
NCT00488488 ↗ A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting Completed Pfizer 2006-11-01 To assess the efficacy and safety of Tygacil in the usual German hospital setting. The main goals are: to assess the efficacy of Tygacil under usual care conditions (cure rate); to assess the main side effects observed in daily medical practice (Safety of Tygacil); to determine whether patients are optimally dosed with Tygacil (according to the label) and the proportion of patients receiving a monotherapy versus combination therapy; to observe the potential resistance development against Tygacil in Germany; to determine which antibiotic agents are chosen for a combination therapy with Tygacil; to determine to which antibiotic substance non-responders to Tygacil are switched; to assess the duration of the intravenous therapy with Tygacil and to determine whether and which patients receive an oral antibiotic substance after the therapy with Tygacil; to collect information on profile, comorbidities and characteristics of patients treated with Tygacil.
NCT00600600 ↗ Tigecycline for Treatment of Rapidly Growing Mycobacteria Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 2 2002-04-01 To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
NCT00600600 ↗ Tigecycline for Treatment of Rapidly Growing Mycobacteria Completed The University of Texas Health Science Center at Tyler Phase 2 2002-04-01 To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
NCT00683332 ↗ Post-Marketing Study Of The Safety Of Tygacil (Tigecycline) Completed Pfizer 2007-04-01 The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
NCT00827541 ↗ Post-Authorization Study Evaluating Safety Of Tigecycline Completed Pfizer 2008-08-01 This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and patients' conditions, in order to assess the "real incidence" of adverse events related with tigecycline in these patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tygacil

Condition Name

Condition Name for Tygacil
Intervention Trials
Complicated Skin and Skin Structure Infections 2
Skin Disease, Infectious 2
Infection 2
Intra-Abdominal Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tygacil
Intervention Trials
Infections 10
Infection 10
Communicable Diseases 9
Intraabdominal Infections 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tygacil

Trials by Country

Trials by Country for Tygacil
Location Trials
United States 17
Korea, Republic of 6
Germany 1
South Africa 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tygacil
Location Trials
California 2
New York 2
Michigan 2
Florida 1
Kansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tygacil

Clinical Trial Phase

Clinical Trial Phase for Tygacil
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tygacil
Clinical Trial Phase Trials
Completed 11
Withdrawn 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tygacil

Sponsor Name

Sponsor Name for Tygacil
Sponsor Trials
Pfizer 8
Wyeth is now a wholly owned subsidiary of Pfizer 5
The University of Texas Health Science Center at Tyler 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tygacil
Sponsor Trials
Industry 13
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Baxter
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.